Skip to content

Huffington Post Canada interviews Raphael Hofstein about Canadian venture capital shortage

Raphael Hofstein
Raphael Hofstein, president and CEO of MaRS Innovation

Raphael Hofstein, president and CEO of MaRS Innovation, was interviewed by Huffington Post Canada business reporter Rachel Mendleson for an article about Canada’s innovation gap and the shortage of Canadian venture capital:

One of the best ways to [raise venture capital], said Raphael Hofstein, President and CEO of Toronto-based MaRS Innovation, is to increase government investment, a lesson he learned while helping to create a life sciences early-stage fund in Israel several years ago.

“Everybody told us — institutions, industry — that they will not participate unless government has a piece of the pie. So governments have to participate, certainly in the early stage,” he said.

Continue Reading

VP Joel Liederman: MaRS Innovation, Canadian Research and the Commercialization Test

Joel Liederman, vice-president of business development and physical sciences
Joel Liederman, MI’s vice-president of business development and physical sciences

Joel Liederman, MaRS Innovation’s vice-president of Business Development and Physical Sciences, was quoted in a National Post article, published August 13, probing whether Canadian research is passing the commercialization test.

Here’s an excerpt:

While academics have often been accused of being disconnected from the real world and consuming themselves with the theoretical, it’s hard to imagine they would be able to get away with squandering funding dollars on things that make them go hmmm, particularly in light of the hyper focus on fiscal prudence.

Indeed, those who are intimately involved in attempting to bridge the commercialization gap agree that the old system of leaving university professors to their own devices had long ago been shelved in favour of a more judicious approach.

Joel Liederman, vice president of Business Development and Physical Sciences at MaRS Innovation, says there’s no doubt that much of the R&D being performed in Canada never makes it past the patent stage, but not because its origins were founded on theory instead of commercial need.

Continue Reading

Vice-President Joel Liederman to participate in Financial Post’s live chat on Canadian commercialization challenges

Joel Liederman
Joel Liederman, vice-president of Business Development and Physical Sciences at MaRS Innovation

Joel Liederman, MaRS Innovation’s vice-president of Business Development and Physical Sciences, is participating in a live chat on the Financial Post‘s website.

The chat will take place on June 28, 2012 at 2 pm.

Topic: Why Canada can’t do anything with its big ideas

When it comes to academic research and the development or discovery of new concepts or product models, there are few countries in the world that can hold a candle to Canada.

Continue Reading

MaRS Innovation Forms Strategic Drug-Development Partnership with NovoTek Therapeutics Inc. in China

ScarX logoMaRS Innovation (MI), The Hospital for Sick Children (SickKids) and NovoTek Therapeutics Inc. (NovoTek)  have announced a strategic partnership to co‐develop, and bring to the Chinese market, a novel therapeutic cream aimed at reducing scar formation post surgery.

This project was covered in The Globe and Mail on May 7, 2012.

Continue Reading

Video: Canadian International Council interviews Rafi Hofstein about commercializing Canadian technology

Dr. Raphael Hofstein, president and CEO of MaRS Innovation, spoke to the Canadian International Council about the importance of protecting intellectual property as an important component in commercializing Canadian technologies.

Here’s an excerpt:

Government could be extremely helpful if they created special funds dedicated to covering the costs of patent protection.

Continue Reading

Vasculotide: sanofi-aventis, Sunnybrook and MI – Article in the Globe and Mail

A discovery that could help millions of diabetics worldwide is the subject of a lucrative pharmaceutical deal that will enrich the Toronto hospital that created it – part of a growing trend of selling science to help shore up Canada’s troubled health-care system.

Tuesday’s agreement between Sanofi-Aventis and Sunnybrook Health Sciences Centre on a wound-healing molecule demonstrates how entrepreneurial hospitals can become when the very sustainability of medicare is in question.

But the licensing deal with one of the world’s biggest drug companies is also savvy medically. Until recently, some hospitals were reticent to capitalize on their discoveries, seeing commercialization as unsavoury, but now many believe it’s one of the quickest ways to get a drug to their patients.

Continue Reading
Back To Top